Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01011439|
Recruitment Status : Active, not recruiting
First Posted : November 11, 2009
Results First Posted : October 16, 2018
Last Update Posted : October 16, 2018
|Condition or disease||Intervention/treatment||Phase|
|Thymic Carcinoma||Drug: Milciclib Maleate||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||72 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma Previously Treated With Chemotherapy|
|Actual Study Start Date :||February 22, 2010|
|Actual Primary Completion Date :||May 31, 2017|
|Estimated Study Completion Date :||December 2018|
Experimental: Milciclib Maleate (PHA-848125AC)
100 and 50 mg Capsule 150 mg/day once daily, for 7 consecutive days (days 1 to 7) followed by 7 days of rest (days 8 to 14) in a 2-week cycle
Drug: Milciclib Maleate
150 mg/day once daily, for 7 consecutive days (days 1 to 7) followed by 7 days of rest (days 8 to 14) in a 2-week cycle.
Number of cycles: until disease progression or unacceptable toxicity.
Other Name: PHA-848125AC
- Progression-free Survival Rate at 3 Months [ Time Frame: 3 months since treatment start ]The proportion of successes (i.e. patients alive and progression free at 3 months since treatment start) out of the total number of evaluable patients
- Confirmed Objective Response Rate (ORR) [ Time Frame: Assessments were made every 6 weeks from start date until PD to a maximum duration of 242 weeks or until PD. ]Point and 95% confidence interval estimates was calculated for the objective tumor response rate (confirmed CRs or PRs). The determination of antitumor efficacy was based on objective tumor assessments made according to the RECIST guideline (version 1.1) The analysis was performed in the evaluable population.
- Disease Control Rate [ Time Frame: Assessments were made every 6 weeks from start date until PD to a maximum duration of 242 weeks or until PD. ]Point and 95% confidence interval estimates was calculated for the disease control rate (confirmed CRs / PRs and SD>/= 6 weeks). The analysis was performed in the evaluable populations.
- Progression-free Survival [ Time Frame: Assessments were made every 6 weeks from start date until PD to a maximum duration of 242 weeks or until PD. ]The length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse. In a clinical trial, measuring the progression-free survival is one way to see how well a new treatment works.
- Duration of Response [ Time Frame: Assessments were made every 6 weeks from start date until PD to a maximum duration of 242 weeks or until PD. ]Assessed in patients achieving a confirmed objective tumor response by RECIST version 1.1 criteria.
- Overall Survival [ Time Frame: Every 6 weeks during Follow-Up until PD or new therapy start; every 6 months thereafter, up to 2 years from the last dose of study drug. ]The length of time from the start of treatment for a disease, such as cancer, to the date in which the patients diagnosed with the disease were still alive.
- Overall Safety Profile (Adverse Events (NCI CTCAE) and Hematological and Blood Chemistry Parameters) [ Time Frame: Adverse events: from date treatment consent signed to 28 days after last dose of study drug; hematology/blood chemistry tests: at baseline and between Day 11-14 of each cycle of a total of 135 two-week cycles. ]
The adverse events (AEs) were coded with the Medical Dictionary for Regulatory Activities (MedDRA) and their severity graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. The following subsets of AEs were considered: serious AEs, AEs with CTCAE grade 3-5, AEs with a relationship to study treatment classified by the Investigator as possible or probable or definite and AEs reported as leading to discontinuation from treatment.
Laboratory test values were graded according to the NCI CTCAE scale, v3.0, whenever possible. For each laboratory test included in the NCI CTCAE system, the incidence of abnormalities was evaluated by considering the worst occurrence for each patient throughout the whole treatment period.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01011439
|United States, Arizona|
|TGen Clinical Research Services at Scottsdale Healthcare|
|Scottsdale, Arizona, United States, 85258|
|United States, Maryland|
|NIH, Center for Cancer Research, Medical Oncology|
|Bethesda, Maryland, United States, 20892|
|Toulouse Cedex, France, 31059|
|Institut de cancerologie Gustave Roussy|
|Villejuif Cedex, France, 94805|
|Fondazione IRCCS Istituto Nazionale dei Tumori di Milano|
|Milano, (mi), Italy, 20133|
|Azienda Ospedaliera San Luigi Gonzaga|
|Orbassano, Italy, 10043|
|Principal Investigator:||Glen Weiss, MD||Scottsdale Clinical Research Institute, USA|
|Principal Investigator:||Benjamin Besse, MD||Institut Gustave Roussy, Villejuif, France|
|Principal Investigator:||Julien Mazières, MD||Hopital Larrey CHU, Toulouse, France|
|Principal Investigator:||Silvia Novello, MD||Ospedale San Luigi Gonzaga, Orbassano, Italy|
|Principal Investigator:||Arun Rajan, MD.||National Cancer Institute (NCI)|
|Principal Investigator:||Marina C Garassino, MD||Fondazione IRCCS Istituto Nazionale dei Tumori di Milano|